MiR-192 attenuates high glucose-induced pyroptosis in retinal pigment epithelial cells via inflammasome modulation

References

• van Dooren FE, Nefs G, Schram MT, et al. Depression and risk of mortality in people with diabetes mellitus: a systematic review and meta-analysis. PLoS One. 2013;8(3):e57058.
   PubMed Web of Science ®Google Scholar
• Zhao F, Gao X, Ge X, et al. Cyanidin-3-o-glucoside (C3G) inhibits vascular leakage regulated by microglial activation in early diabetic retinopathy and neovascularization in advanced diabetic retinopathy. Bioengineered. 2021;12(2):9266–9278.
   PubMed Web of Science ®Google Scholar
• Lim RR, Wieser ME, Ganga RR, et al. NOD-like Receptors in the Eye: uncovering Its Role in Diabetic Retinopathy. Int J Mol Sci. 2020;21(3):899.
   PubMed Web of Science ®Google Scholar
• Liu X, Cui H. The palliative effects of folic acid on retinal microvessels in diabetic retinopathy via regulating the metabolism of DNA methylation and hydroxymethylation. Bioengineered. 2021 Dec;12(2):10766–10774.
   PubMed Web of Science ®Google Scholar
• Ting DS, Cheung GC, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol. 2016;44(4):260–277.
   PubMed Web of Science ®Google Scholar
• Wang W, Lo ACY. Diabetic Retinopathy: pathophysiology and Treatments. Int J Mol Sci. 2018;19(6):1816.
   PubMed Web of Science ®Google Scholar
• Wong TY, Cheung CM, Larsen M, et al. Diabetic retinopathy. Nat Rev Dis Primers. 2016;2:16012.
   PubMed Web of Science ®Google Scholar
• Tarr JM, Kaul K, Chopra M, et al. Pathophysiology of diabetic retinopathy. ISRN Ophthalmol. 2013;2013:343560.
   PubMedGoogle Scholar
• Chatziralli I, Sergentanis TN, Crosby-Nwaobi R, et al. Model for Risk-Based Screening of Diabetic Retinopathy in People With Newly-Diagnosed Type 2 Diabetes Mellitus. Invest Ophthalmol Vis Sci. 2017;58(6):BIO99–BIO105.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li M, Wang W, et al. Carvedilol activates nuclear factor E2-related factor 2/ antioxidant response element pathway to inhibit oxidative stress and apoptosis of retinal pigment epithelial cells induced by high glucose. Bioengineered. 2022;13(1):735–745.
   PubMed Web of Science ®Google Scholar
• Yang F, Qin Y, Wang Y, et al. LncRNA KCNQ1OT1 Mediates Pyroptosis in Diabetic Cardiomyopathy. Cell Physiol Biochem. 2018;50(4):1230–1244.
   PubMedGoogle Scholar
• Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol. 2009;7(2):99–109.
   PubMed Web of Science ®Google Scholar
• Zhang L, Yuan M, Zhang L, et al. Adiponectin alleviates NLRP3-inflammasome-mediated pyroptosis of aortic endothelial cells by inhibiting FoxO4 in arteriosclerosis. Biochem Biophys Res Commun. 2019;514(1):266–272.
   PubMed Web of Science ®Google Scholar
• Zeng R, Luo DX, Li HP, et al. MicroRNA-135b alleviates MPP+-mediated Parkinson’s disease in in vitro model through suppressing FoxO1-induced NLRP3 inflammasome and pyroptosis. J Clin Neurosci. 2019;65:125–133.
   PubMed Web of Science ®Google Scholar
• Dubois H, Sorgeloos F, Sarvestani ST, et al. Nlrp3 inflammasome activation and Gasdermin D-driven pyroptosis are immunopathogenic upon gastrointestinal norovirus infection. PLoS Pathog. 2019;15(4):e1007709.
   PubMed Web of Science ®Google Scholar
• Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger? Science. 2010;327(5963):296–300.
   PubMed Web of Science ®Google Scholar
• Xue Y, Enosi Tuipulotu D, Tan WH, et al. Emerging Activators and Regulators of Inflammasomes and Pyroptosis. Trends Immunol. 2019;40(11):1035–1052.
   PubMed Web of Science ®Google Scholar
• Shi J, Zhao Y, Wang K, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526(7575):660–665.
   PubMed Web of Science ®Google Scholar
• Zeng C, Wang R, Tan H. Role of Pyroptosis in Cardiovascular Diseases and its Therapeutic Implications. Int J Biol Sci. 2019;15(7):1345–1357.
   PubMed Web of Science ®Google Scholar
• Lee C, Do HTT, Her J, et al. Inflammasome as a promising therapeutic target for cancer. Life Sci. 2019;231:116593.
   PubMed Web of Science ®Google Scholar
• Tang B, Deng CQ. Pyroptosis and stroke. Sheng Li Xue Bao. 2018;70(1):93–98.
   PubMedGoogle Scholar
• Singh LP, Devi TS, Yumnamcha T. The Role of Txnip in Mitophagy Dysregulation and Inflammasome Activation in Diabetic Retinopathy: a New Perspective. JOJ Ophthalmol. 2017;4(4). doi:10.19080/jojo.2017.04.555643.
   PubMedGoogle Scholar
• Hwang N, Chung SW. Sulfasalazine attenuates tamoxifen-induced toxicity in human retinal pigment epithelial cells. BMB Rep. 2020;53(5):284–289.
   PubMed Web of Science ®Google Scholar
• Beranova-Giorgianni S, Giorgianni F. Proteomics of Human Retinal Pigment Epithelium (RPE) Cells. Proteomes. 2018;6(2):22.
   PubMed Web of Science ®Google Scholar
• Xi X, Yang Y, Ma J, et al. MiR-130a alleviated high-glucose induced retinal pigment epithelium (RPE) death by modulating TNF-α/SOD1/ROS cascade mediated pyroptosis. Biomed Pharmacother. 2020;125:109924.
   PubMed Web of Science ®Google Scholar
• Shukla GC, Singh J, Barik S. MicroRNAs: processing, Maturation, Target Recognition and Regulatory Functions. Mol Cell Pharmacol. 2011;3(3):83–92.
   PubMedGoogle Scholar
• Trotta MC, Gesualdo C, Platania CBM, et al. Circulating miRNAs in diabetic retinopathy patients: prognostic markers or pharmacological targets? Biochem Pharmacol. 2021 Apr;186:114473.
   PubMed Web of Science ®Google Scholar
• Platania CBM, Maisto R, Trotta MC, et al. Retinal and circulating miRNA expression patterns in diabetic retinopathy: an in silico and in vivo approach. Br J Pharmacol. 2019;176(13):2179–2194.
   PubMed Web of Science ®Google Scholar
• Martinez B, Peplow PV. MicroRNAs as biomarkers of diabetic retinopathy and disease progression. Neural Regen Res. 2019;14(11):1858–1869.
   PubMed Web of Science ®Google Scholar
• Pastukh N, Meerson A, Kalish D, et al. Serum miR-122 levels correlate with diabetic retinopathy. Clin Exp Med. 2019;19(2):255–260.
   PubMed Web of Science ®Google Scholar
• Wu J, Wang R, Ye Z, et al. Protective effects of methane-rich saline on diabetic retinopathy via anti-inflammation in a streptozotocin-induced diabetic rat model. Biochem Biophys Res Commun. 2015;466(2):155–161.
   PubMed Web of Science ®Google Scholar
• Lian C, Sun J, Guan W, et al. Circular RNA circHIPK3 Activates Macrophage NLRP3 Inflammasome and TLR4 Pathway in Gouty Arthritis via Sponging miR-561 and miR-192. Inflammation. 2021;44(5):2065–2077.
   PubMed Web of Science ®Google Scholar
• Gu C, Zhang H, Gao Y. Adipose mesenchymal stem cells-secreted extracellular vesicles containing microRNA-192 delays diabetic retinopathy by targeting ITGA1. J Cell Physiol. 2021;236(7):5036–5051.
   PubMed Web of Science ®Google Scholar
• Schneider KS, Groß CJ, Dreier RF, et al. The Inflammasome Drives GSDMD-Independent Secondary Pyroptosis and IL-1 Release in the Absence of Caspase-1 Protease Activity. Cell Rep. 2017 Dec 26; 21(13):3846–3859.
   PubMed Web of Science ®Google Scholar
• Mascarenhas DPA, Cerqueira DM, Pereira MSF, et al. Inhibition of caspase-1 or gasdermin-D enable caspase-8 activation in the Naip5/NLRC4/ASC inflammasome. PLoS Pathog. 2017;13(8):e1006502.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Sorrentino FS, Matteini S, Bonifazzi C, et al. Diabetic retinopathy and endothelin system: microangiopathy versus endothelial dysfunction. Eye (Lond). 2018;32(7):1157–1163.
   PubMed Web of Science ®Google Scholar
• Nentwich MM, Ulbig MW. Diabetic retinopathy - ocular complications of diabetes mellitus. World J Diabetes. 2015;6(3):489–499.
   PubMed Web of Science ®Google Scholar
• Whitehead M, Wickremasinghe S, Osborne A, et al. Diabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies. Expert Opin Biol Ther. 2018;18(12):1257–1270.
   PubMed Web of Science ®Google Scholar
• Bandello F, Lattanzio R, Zucchiatti I, et al. Pathophysiology and treatment of diabetic retinopathy. Acta Diabetol. 2013;50(1):1–20.
   PubMed Web of Science ®Google Scholar
• Bucolo C, Gozzo L, Longo L, et al. Long-term efficacy and safety profile of multiple injections of intravitreal dexamethasone implant to manage diabetic macular edema: a systematic review of real-world studies. J Pharmacol Sci. 2018;138(4):219–232.
   PubMed Web of Science ®Google Scholar
• Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366(13):1227–1239.
   PubMed Web of Science ®Google Scholar
• Kim DI, Park MJ, Lim SK, et al. High-glucose-induced CARM1 expression regulates apoptosis of human retinal pigment epithelial cells via histone 3 arginine 17 dimethylation: role in diabetic retinopathy. Arch Biochem Biophys. 2014;560:36–43.
   PubMed Web of Science ®Google Scholar
• Kim DI, Park MJ, Choi JH, et al. Hyperglycemia-induced GLP-1R downregulation causes RPE cell apoptosis. Int J Biochem Cell Biol. 2015;59:41–51.
   PubMed Web of Science ®Google Scholar
• Zha X, Xi X, Fan X, et al. Overexpression of METTL3 attenuates high-glucose induced RPE cell pyroptosis by regulating miR-25-3p/PTEN/Akt signaling cascade through DGCR8. Aging (Albany NY). 2020;12(9):8137–8150.
   PubMedGoogle Scholar
• Tenconi PE, Bermúdez V, Oresti GM, et al. High glucose-induced phospholipase D activity in retinal pigment epithelium cells: new insights into the molecular mechanisms of diabetic retinopathy. Exp Eye Res. 2019;184:243–257.
   PubMed Web of Science ®Google Scholar
• Bahrami B, Shen W, Zhu L, et al. Effects of VEGF inhibitors on human retinal pigment epithelium under high glucose and hypoxia. Clin Exp Ophthalmol. 2019;47(8):1074–1081.
   PubMed Web of Science ®Google Scholar
• Wang P, Chen F, Wang W. Hydrogen Sulfide Attenuates High Glucose-Induced Human Retinal Pigment Epithelial Cell Inflammation by Inhibiting ROS Formation and NLRP3 Inflammasome Activation. Mediators Inflamm. 2019;2019:8908960.
   PubMed Web of Science ®Google Scholar
• Fan B, Luk AOY, Chan JCN, et al. MicroRNA and Diabetic Complications: a Clinical Perspective. Antioxid Redox Signal. 2018;29(11):1041–1063.
   PubMed Web of Science ®Google Scholar
• Delić D, Eisele C, Schmid R, et al. Urinary Exosomal miRNA Signature in Type II Diabetic Nephropathy Patients. PLoS One. 2016;11(3):e0150154.
   PubMed Web of Science ®Google Scholar
• Li X, Yu ZW, Wang Y, et al. MicroRNAs: potential Targets in Diabetic Retinopathy. Horm Metab Res. 2020;52(3):142–148.
   PubMed Web of Science ®Google Scholar
• Assmann TS, Recamonde-Mendoza M, de Souza BM, et al. MicroRNAs and diabetic kidney disease: systematic review and bioinformatic analysis. Mol Cell Endocrinol. 2018;477:90–102.
   PubMed Web of Science ®Google Scholar
• Chien HY, Chen CY, Chiu YH, et al. Differential microRNA Profiles Predict Diabetic Nephropathy Progression in Taiwan. Int J Med Sci. 2016;13(6):457–465.
   PubMed Web of Science ®Google Scholar
• Liu F, Zhang ZP, Xin GD, et al. Wang ZX. miR-192 prevents renal tubulointerstitial fibrosis in diabetic nephropathy by targeting Egr1. Eur Rev Med Pharmacol Sci. 2018;22(13):4252–4260.
   PubMed Web of Science ®Google Scholar
• Wang LP, Gao YZ, Song B, et al. MicroRNAs in the Progress of Diabetic Nephropathy: a Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med. 2019;2019:3513179.
   PubMed Web of Science ®Google Scholar
• Al-Kafaji G, Al-Muhtaresh HA. Expression of microRNA‑377 and microRNA‑192 and their potential as blood‑based biomarkers for early detection of type 2 diabetic nephropathy. Mol Med Rep. 2018;18(1):1171–1180.
   PubMed Web of Science ®Google Scholar
• Zhong H, Tang HF, Kai Y. N6-methyladenine RNA Modification (m6A): an Emerging Regulator of Metabolic Diseases. Curr Drug Targets. 2020;21(11):1056–1067.
   PubMed Web of Science ®Google Scholar
• Niu Y, Lin Z, Wan A, et al. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3. Mol Cancer. 2019;18(1):46.
   PubMed Web of Science ®Google Scholar
• Cao G, Li HB, Yin Z, et al. Recent advances in dynamic m6A RNA modification. Open Biol. 2016r;6(4):160003.
   PubMed Web of Science ®Google Scholar
• Jia G, Fu Y, Zhao X, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011;7(12):885–887.
   PubMed Web of Science ®Google Scholar
• Montesanto A, Bonfigli AR, Crocco P, et al. Genes associated with Type 2 Diabetes and vascular complications. Aging (Albany NY). 2018;10(2):178–196.
   PubMedGoogle Scholar